» Articles » PMID: 17374857

Sequential Changes After Radiofrequency Ablation and Cryoablation of Renal Neoplasms: Role of CT and MR Imaging

Overview
Journal Radiographics
Specialty Radiology
Date 2007 Mar 22
PMID 17374857
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Radiofrequency (RF) ablation and cryoablation are increasingly being used as minimally invasive treatments for renal malignancies. Accurate assessment of ablated tumors at postprocedural imaging is essential for evaluating the adequacy of treatment and guiding further management. Renal tumors treated with RF ablation or cryoablation appear as low-attenuation regions at computed tomography (CT) and, relative to renal parenchyma, are generally hypointense at T2-weighted magnetic resonance (MR) imaging and iso- to hyperintense at T1-weighted imaging. The use of intravenous contrast material is essential for the evaluation of possible residual or recurrent tumor. At follow-up CT or MR imaging, successfully treated renal tumors appear as focal masses that demonstrate no evidence of contrast enhancement and that frequently decrease in size over time, whereas residual or recurrent tumor can be detected as abnormal foci of contrast enhancement. Follow-up surveillance imaging is warranted because long-term results for renal tumor ablation are not known, and evaluation for residual, recurrent, or metachronous tumor is essential.

Citing Articles

Ablative Treatments for Small Renal Masses and Management of Recurrences: A Comprehensive Review.

Aveta A, Iossa V, Spena G, Conforti P, Pagano G, Dinacci F Life (Basel). 2024; 14(4).

PMID: 38672721 PMC: 11050889. DOI: 10.3390/life14040450.


Contrast enhancement early after renal malignancy cryoablation: imaging findings associated with benignity.

Grand T, Delavaud C, Dariane C, Ramtohul T, Guinebert S, Helenon O Eur Radiol. 2023; 33(12):8703-8714.

PMID: 37405502 DOI: 10.1007/s00330-023-09814-7.


Intraoperative MRI-derived volumetric ablation margins and initial correlation with local outcome after MRI-guided cryoablation of renal tumors.

de Jager N, van Oostenbrugge T, Patz T, Jenniskens S, Futterer J, Langenhuijsen J Cancer Imaging. 2023; 23(1):31.

PMID: 36998028 PMC: 10064595. DOI: 10.1186/s40644-023-00546-x.


Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer.

Hannan R, McLaughlin M, Pop L, Pedrosa I, Kapur P, Garant A Eur Urol. 2023; 84(3):275-286.

PMID: 36898872 PMC: 10440291. DOI: 10.1016/j.eururo.2023.02.016.


Imaging considerations for thermal and radiotherapy ablation of primary and metastatic renal cell carcinoma.

Haroon M, Sathiadoss P, Hibbert R, Jeyaraj S, Lim C, Schieda N Abdom Radiol (NY). 2021; 46(11):5386-5407.

PMID: 34245341 DOI: 10.1007/s00261-021-03178-6.